Renalytix (RENX) Competitors

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership.

Do analysts prefer KOO or RENX?

Kooth currently has a consensus price target of GBX 456.67, indicating a potential upside of 206.73%. Given Kooth's stronger consensus rating and higher probable upside, analysts plainly believe Kooth is more favorable than Renalytix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kooth	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Renalytix	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to KOO or RENX?

In the previous week, Kooth had 12 more articles in the media than Renalytix. MarketBeat recorded 12 mentions for Kooth and 0 mentions for Renalytix. Kooth's average media sentiment score of 0.18 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the media.

Company	Overall Sentiment
Kooth	Neutral
Renalytix	Neutral

Is KOO or RENX more profitable?

Kooth has a net margin of 7.89% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Kooth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kooth	7.89%	18.59%	10.12%
Renalytix	-1,191.75%	293.20%	-93.54%

Do insiders & institutionals believe in KOO or RENX?

65.0% of Kooth shares are owned by institutional investors. Comparatively, 28.4% of Renalytix shares are owned by institutional investors. 17.3% of Kooth shares are owned by company insiders. Comparatively, 35.7% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer KOO or RENX?

Renalytix received 9 more outperform votes than Kooth when rated by MarketBeat users. However, 93.33% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote.

Company	Underperform	Outperform
Kooth	Outperform Votes 14 93.33%	Underperform Votes 1 6.67%
Renalytix	Outperform Votes 23 74.19%	Underperform Votes 8 25.81%

Which has more risk & volatility, KOO or RENX?

Kooth has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.

Which has preferable valuation & earnings, KOO or RENX?

Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kooth	£50.72M	1.08	£4.00M	£10.64	13.99
Renalytix	£9.22M	3.60	-£109.93M	-£21.19	-0.38

Summary

Kooth beats Renalytix on 13 of the 18 factors compared between the two stocks.